Related Experiment Video
Updated: Feb 1, 2026

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst
Published on: March 31, 2023
Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients
1Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; and.
Abstract:
With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.
Insights
The therapeutic landscape for multiple myeloma has evolved with new drug approvals. This guide details a 2018 approach to treating transplant-eligible patients with these novel therapies.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- The treatment of multiple myeloma has been significantly impacted by recent advancements in therapeutic options.
- New classes of drugs, including proteasome inhibitors, immune-modulatory drugs, and monoclonal antibodies, have been approved.
Purpose of the Study:
- To provide a personal, case-based guide on managing multiple myeloma therapy.
- To outline an approach for transplant-eligible patients in the context of 2018 treatment options.
Main Methods:
- A case-based approach is utilized to illustrate therapeutic decision-making.
- The guide incorporates newly approved agents such as carfilzomib, ixazomib, pomalidomide, elotuzimab, and daratumumab.
Main Results:
- The evolving treatment landscape necessitates personalized therapeutic strategies.
- Effective management involves integrating novel agents into treatment regimens.
Conclusions:
- A structured, case-based approach is essential for optimizing multiple myeloma treatment.
- The integration of novel therapies offers improved management options for transplant-eligible patients.
Related Concept Videos
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Inclusive Fitness
Diagnosing Acidosis and Alkalosis
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
Goodness-of-Fit Test
Multiple Allele Traits
Expected Frequencies in Goodness-of-Fit Tests

